ENOVIS CORP (ENOV) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:ENOV - US1940141062 - Common Stock
ENOV Key Statistics, Chart & Performance
The current stock price of ENOV is 29.68 USD. In the past month the price increased by 7.26%. In the past year, price decreased by -33.71%.
ENOV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About ENOV
Company Profile
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,367 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
Company Info
ENOVIS CORP
2711 Centerville Road, Suite 400
Wilmington DELAWARE US
Employees: 7367
Phone: 13022529160
ENOVIS CORP / ENOV FAQ
What does ENOVIS CORP do?
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,367 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
What is the stock price of ENOVIS CORP today?
The current stock price of ENOV is 29.68 USD. The price increased by 2.95% in the last trading session.
What is the dividend status of ENOVIS CORP?
ENOV does not pay a dividend.
What is the ChartMill rating of ENOVIS CORP stock?
ENOV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for ENOVIS CORP?
ENOVIS CORP (ENOV) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the growth outlook for ENOVIS CORP?
The Revenue of ENOVIS CORP (ENOV) is expected to grow by 7.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for ENOV stock?
ENOVIS CORP (ENOV) will report earnings on 2026-02-24, after the market close.
ENOV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ENOV. When comparing the yearly performance of all stocks, ENOV is a bad performer in the overall market: 84.6% of all stocks are doing better.
ENOV Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ENOV. ENOV has a medium profitability rating, but doesn't score so well on its financial health evaluation.
ENOV Financial Highlights
Over the last trailing twelve months ENOV reported a non-GAAP Earnings per Share(EPS) of 3.33. The EPS increased by 26.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.84% | ||
| ROE | -67.66% | ||
| Debt/Equity | 0.66 |
ENOV Forecast & Estimates
17 analysts have analysed ENOV and the average price target is 47.94 USD. This implies a price increase of 61.52% is expected in the next year compared to the current price of 29.68.
For the next year, analysts expect an EPS growth of 14.67% and a revenue growth 7.42% for ENOV